Clinical Study of “Lingqi Huangban Granule” in Treating Choroidal Neovascularisation in Pathologic Myopia

Objectives: To study the therapeutic effects of “Lingqi Huangban Granule” (LQHB) combined withintravitreal ranibizumab injection (IVR) for choroidal neovascularisation (CNV)in pathologic myopia (PM). Methods:This was a prospective, comparative, interventional study. Eighty eyes ofeighty consecutive patients with myopic CNV were randomized into control group(IVR, 40 eyes) and integrative therapy group (IVR + LQHB, 40 eyes), each with afollow-up period of 12 months. IVR was given with an “on demand” regimen (Pro re nata, PRN). Final best corrected visual acuity (BCVA)and its change from baseline were the main outcome measures. Changes in opticalcoherence tomography (OCT) and central retinal thickness (CRT) were thesecondary outcome measures. Results:BCVA of patients in the integrative group improved significantly (from 47.10 ± 13.51 letters to 90.72 ± 12.98 letter, P 0.05), more than in the control group (from 42.90 ± 13.18 letters to 69.18±13.21letters, P 0.05) since the third month after the initial treatment to the end of thefollow-up. Mean OCT CRT reduced from 364.75 ± 69.31 to 278.93 ± 33.05 um (P 0.05) in the control group and from 370.73 ± 65.31 to 271.73 ± 46.44 um (P 0.05) in the integrative group, respectively. Themean number of intravitreal injections in the 1-year follow-up was also reduced.No ocular or systemic side effects were observed. Conclusion: LQHB combinedwith IVR therapy was an effective treatment for stabilizing and improvingvision with fewer intravitreal injections. It appears to be an interestingoption for this type of patient.